Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Genetically manipulated phages with improved pH resistance for oral administration in veterinary medicine.

Nobrega FL, Costa AR, Santos JF, Siliakus MF, van Lent JW, Kengen SW, Azeredo J, Kluskens LD.

Sci Rep. 2016 Dec 15;6:39235. doi: 10.1038/srep39235.

2.

Screening and characterization of novel specific peptides targeting MDA-MB-231 claudin-low breast carcinoma by computer-aided phage display methodologies.

Nobrega FL, Ferreira D, Martins IM, Suarez-Diez M, Azeredo J, Kluskens LD, Rodrigues LR.

BMC Cancer. 2016 Nov 14;16(1):881.

3.

Selection of Novel Peptides Homing the 4T1 CELL Line: Exploring Alternative Targets for Triple Negative Breast Cancer.

Silva VL, Ferreira D, Nobrega FL, Martins IM, Kluskens LD, Rodrigues LR.

PLoS One. 2016 Aug 22;11(8):e0161290. doi: 10.1371/journal.pone.0161290. eCollection 2016.

4.

Structural and Enzymatic Characterization of ABgp46, a Novel Phage Endolysin with Broad Anti-Gram-Negative Bacterial Activity.

Oliveira H, Vilas Boas D, Mesnage S, Kluskens LD, Lavigne R, Sillankorva S, Secundo F, Azeredo J.

Front Microbiol. 2016 Feb 26;7:208. doi: 10.3389/fmicb.2016.00208. eCollection 2016.

5.

Unexploited opportunities for phage therapy.

Oliveira H, Sillankorva S, Merabishvili M, Kluskens LD, Azeredo J.

Front Pharmacol. 2015 Sep 7;6:180. doi: 10.3389/fphar.2015.00180. eCollection 2015. No abstract available.

6.

Correction: The First Paenibacillus larvae Bacteriophage Endolysin (PlyPl23) with High Potential to Control American Foulbrood.

Oliveira A, Leite M, Kluskens LD, Santos SB, Melo LD, Azeredo J.

PLoS One. 2015 Aug 14;10(8):e0136331. doi: 10.1371/journal.pone.0136331. eCollection 2015. No abstract available.

7.

Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.

Mendes TF, Kluskens LD, Rodrigues LR.

Adv Sci (Weinh). 2015 Jul 17;2(11):1500053. eCollection 2015 Nov.

8.

The First Paenibacillus larvae Bacteriophage Endolysin (PlyPl23) with High Potential to Control American Foulbrood.

Oliveira A, Leite M, Kluskens LD, Santos SB, Melo LD, Azeredo J.

PLoS One. 2015 Jul 13;10(7):e0132095. doi: 10.1371/journal.pone.0132095. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0136331.

9.

Transformation of Escherichia coli JM109 using pUC19 by the Yoshida effect.

Mendes GP, Vieira PS, Lanceros-Méndez S, Kluskens LD, Mota M.

J Microbiol Methods. 2015 Aug;115:1-5. doi: 10.1016/j.mimet.2015.05.012. Epub 2015 May 9.

PMID:
25966644
10.

Heterologous production of caffeic acid from tyrosine in Escherichia coli.

Rodrigues JL, Araújo RG, Prather KL, Kluskens LD, Rodrigues LR.

Enzyme Microb Technol. 2015 Apr;71:36-44. doi: 10.1016/j.enzmictec.2015.01.001. Epub 2015 Jan 14.

PMID:
25765308
11.

Revisiting phage therapy: new applications for old resources.

Nobrega FL, Costa AR, Kluskens LD, Azeredo J.

Trends Microbiol. 2015 Apr;23(4):185-91. doi: 10.1016/j.tim.2015.01.006. Epub 2015 Feb 21. Review.

PMID:
25708933
12.

Production of curcuminoids from tyrosine by a metabolically engineered Escherichia coli using caffeic acid as an intermediate.

Rodrigues JL, Araújo RG, Prather KL, Kluskens LD, Rodrigues LR.

Biotechnol J. 2015 Apr;10(4):599-609. doi: 10.1002/biot.201400637. Epub 2015 Feb 18.

PMID:
25641677
13.

Heterologous production of curcuminoids.

Rodrigues JL, Prather KL, Kluskens LD, Rodrigues LR.

Microbiol Mol Biol Rev. 2015 Mar;79(1):39-60. doi: 10.1128/MMBR.00031-14. Review.

14.

A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids.

Oliveira H, Thiagarajan V, Walmagh M, Sillankorva S, Lavigne R, Neves-Petersen MT, Kluskens LD, Azeredo J.

PLoS One. 2014 Oct 7;9(10):e108376. doi: 10.1371/journal.pone.0108376. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e115267.

15.

Selection of Escherichia coli heat shock promoters toward their application as stress probes.

Rodrigues JL, Sousa M, Prather KL, Kluskens LD, Rodrigues LR.

J Biotechnol. 2014 Oct 20;188:61-71. doi: 10.1016/j.jbiotec.2014.08.005. Epub 2014 Aug 14.

PMID:
25128614
16.

A bacteriophage detection tool for viability assessment of Salmonella cells.

Fernandes E, Martins VC, Nóbrega C, Carvalho CM, Cardoso FA, Cardoso S, Dias J, Deng D, Kluskens LD, Freitas PP, Azeredo J.

Biosens Bioelectron. 2014 Feb 15;52:239-46. doi: 10.1016/j.bios.2013.08.053. Epub 2013 Sep 7.

PMID:
24055938
17.

Molecular aspects and comparative genomics of bacteriophage endolysins.

Oliveira H, Melo LD, Santos SB, Nóbrega FL, Ferreira EC, Cerca N, Azeredo J, Kluskens LD.

J Virol. 2013 Apr;87(8):4558-70. doi: 10.1128/JVI.03277-12. Epub 2013 Feb 13.

18.

Complete genome sequence of the lytic Pseudomonas fluorescens phage ϕIBB-PF7A.

Sillankorva S, Kluskens LD, Lingohr EJ, Kropinski AM, Neubauer P, Azeredo J.

Virol J. 2011 Mar 26;8:142. doi: 10.1186/1743-422X-8-142.

19.

Requirements of the engineered leader peptide of nisin for inducing modification, export, and cleavage.

Plat A, Kluskens LD, Kuipers A, Rink R, Moll GN.

Appl Environ Microbiol. 2011 Jan;77(2):604-11. doi: 10.1128/AEM.01503-10. Epub 2010 Nov 19.

20.

Molecular characterization of the glucose isomerase from the thermophilic bacterium Fervidobacterium gondwanense.

Kluskens LD, Zeilstra J, Geerling AC, de Vos WM, van der Oost J.

Environ Technol. 2010 Sep;31(10):1083-90. doi: 10.1080/09593330903486673.

PMID:
20718290
21.

Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog.

Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN, Haas M.

J Pharmacol Exp Ther. 2009 Mar;328(3):849-54. doi: 10.1124/jpet.108.146431. Epub 2008 Nov 26.

PMID:
19038778
22.

Mechanistic dissection of the enzyme complexes involved in biosynthesis of lacticin 3147 and nisin.

Kuipers A, Meijer-Wierenga J, Rink R, Kluskens LD, Moll GN.

Appl Environ Microbiol. 2008 Nov;74(21):6591-7. doi: 10.1128/AEM.01334-08. Epub 2008 Sep 12.

23.

Influence of shifting positions of Ser, Thr, and Cys residues in prenisin on the efficiency of modification reactions and on the antimicrobial activities of the modified prepeptides.

Lubelski J, Overkamp W, Kluskens LD, Moll GN, Kuipers OP.

Appl Environ Microbiol. 2008 Aug;74(15):4680-5. doi: 10.1128/AEM.00112-08. Epub 2008 Jun 6.

24.

NisC, the cyclase of the lantibiotic nisin, can catalyze cyclization of designed nonlantibiotic peptides.

Rink R, Kluskens LD, Kuipers A, Driessen AJ, Kuipers OP, Moll GN.

Biochemistry. 2007 Nov 13;46(45):13179-89. Epub 2007 Oct 12.

PMID:
17929939
25.

Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and B and by C-terminal truncation.

Rink R, Wierenga J, Kuipers A, Kluskens LD, Driessen AJ, Kuipers OP, Moll GN.

Appl Environ Microbiol. 2007 Sep;73(18):5809-16. Epub 2007 Jul 27.

26.

Production of dehydroamino acid-containing peptides by Lactococcus lactis.

Rink R, Wierenga J, Kuipers A, Kluskens LD, Driessen AJ, Kuipers OP, Moll GN.

Appl Environ Microbiol. 2007 Mar;73(6):1792-6. Epub 2007 Jan 19.

27.

Sec-mediated transport of posttranslationally dehydrated peptides in Lactococcus lactis.

Kuipers A, Wierenga J, Rink R, Kluskens LD, Driessen AJ, Kuipers OP, Moll GN.

Appl Environ Microbiol. 2006 Dec;72(12):7626-33. Epub 2006 Oct 13.

28.

Characterization and mode of action of an exopolygalacturonase from the hyperthermophilic bacterium Thermotoga maritima.

Kluskens LD, van Alebeek GJ, Walther J, Voragen AG, de Vos WM, van der Oost J.

FEBS J. 2005 Nov;272(21):5464-73.

29.

Post-translational modification of therapeutic peptides by NisB, the dehydratase of the lantibiotic nisin.

Kluskens LD, Kuipers A, Rink R, de Boef E, Fekken S, Driessen AJ, Kuipers OP, Moll GN.

Biochemistry. 2005 Sep 27;44(38):12827-34.

PMID:
16171398
30.

Cloning and expression of islandisin, a new thermostable subtilisin from Fervidobacterium islandicum, in Escherichia coli.

Gödde C, Sahm K, Brouns SJ, Kluskens LD, van der Oost J, de Vos WM, Antranikian G.

Appl Environ Microbiol. 2005 Jul;71(7):3951-8.

31.

NisT, the transporter of the lantibiotic nisin, can transport fully modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides.

Kuipers A, de Boef E, Rink R, Fekken S, Kluskens LD, Driessen AJ, Leenhouts K, Kuipers OP, Moll GN.

J Biol Chem. 2004 May 21;279(21):22176-82. Epub 2004 Mar 24.

32.

Crystal structure of fervidolysin from Fervidobacterium pennivorans, a keratinolytic enzyme related to subtilisin.

Kim JS, Kluskens LD, de Vos WM, Huber R, van der Oost J.

J Mol Biol. 2004 Jan 16;335(3):787-97.

PMID:
14687574
33.

Molecular and biochemical characterization of the thermoactive family 1 pectate lyase from the hyperthermophilic bacterium Thermotoga maritima.

Kluskens LD, van Alebeek GJ, Voragen AG, de Vos WM, van der Oost J.

Biochem J. 2003 Mar 1;370(Pt 2):651-9.

34.

Molecular characterization of fervidolysin, a subtilisin-like serine protease from the thermophilic bacterium Fervidobacterium pennivorans.

Kluskens LD, Voorhorst WG, Siezen RJ, Schwerdtfeger RM, Antranikian G, van der Oost J, de Vos WM.

Extremophiles. 2002 Jun;6(3):185-94. Epub 2002 Feb 14.

PMID:
12072953
35.

Purification, characterization, and molecular modeling of pyrolysin and other extracellular thermostable serine proteases from hyperthermophilic microorganisms.

de Vos WM, Voorhorst WG, Dijkgraaf M, Kluskens LD, Van der Oost J, Siezen RJ.

Methods Enzymol. 2001;330:383-93. No abstract available.

PMID:
11210516
36.

Characterization of beta-glycosylhydrolases from Pyrococcus furiosus.

Kaper T, Verhees CH, Lebbink JH, van Lieshout JF, Kluskens LD, Ward DE, Kengen SW, Beerthuyzen MM, de Vos WM, van der Oost J.

Methods Enzymol. 2001;330:329-46. No abstract available.

PMID:
11210512

Supplemental Content

Loading ...
Support Center